New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?

Abstract

Adjuvant treatment of renal cell carcinoma with vascular endothelial growth factor inhibitors is feasible and effective with careful patient selection and standard dosing levels.

• Authors: Bernard Escudier, Michael Staehler
• Journal: European urology (Eur Urol) Vol. 73 Issue 1 Pg. 1-3 (01 2018) ISSN: 1873-7560 [Electronic] Switzerland
• PMID: 28890247 (Publication Type: Editorial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2017. Published by Elsevier B.V.

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A

Topics

• Angiogenesis Inhibitors (adverse effects, therapeutic use)
• Carcinoma, Renal Cell (drug therapy, metabolism, mortality, pathology)
• Chemotherapy, Adjuvant
• Clinical Trials as Topic
• Disease-Free Survival
• Evidence-Based Medicine
• Humans
• Kidney Neoplasms (drug therapy, metabolism, mortality, pathology)
• Neovascularization, Pathologic
• Signal Transduction (drug effects)
• Time Factors
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors, metabolism)